Site Search

Sacramento, Calif. – June 21, 2022 – The California Assembly Health Committee passed a bill today that would ensure comprehensive biomarker testing is covered by more insurance plans, including Medi-Cal, when ... mutations – which can be measured in blood, tissue or other biospecimens. “Despite its benefits and increasingly important role in cancer care and improving cancer outcomes, 66% of oncology providers reported that insurance coverage is a significant or moderate barrier to appropriate ... the American Cancer Society Cancer Action Network (ACS CAN). “It’s imperative we dismantle cost barriers in order to address and help reduce health disparities.” Communities that have been under-resourced, including communities of color, individuals with limited income, rural residents ...

... testing will enable more patients to access the most effective treatments for their disease and can potentially help achieve the triple aim of health care: better health outcomes, improved quality of life and reduced costs.  This legislation will ensure Iowans covered by Medicaid and state regulated ...

... testing will enable more patients to access the most effective treatments for their disease and can potentially help achieve the triple aim of health care: better health outcomes, improved quality of life and reduced costs.  This legislation will ensure Iowans covered by Medicaid and state regulated ...

... and partners are working together to make sure more Ohioans can benefit from this important testing.   What is Biomarker Testing? In cancer care, biomarkers are often used to help determine the best treatment for a patient . A “ biomarker ” is a sign of a normal biological process, ... are less likely to receive biomarker testing. Improving coverage for and access to biomarker testing across insurance types is key to reducing health disparities. Without action to expand coverage and access to biomarker testing, advances in precision medicine could increase existing disparities in health outcomes by race, ethnicity, income, and geography. Insurance coverage for biomarker testing is failing to keep pace with innovations and ...